Submitted:
17 November 2026
Posted:
18 November 2026
You are already at the latest version
Abstract
Background: Elemental impurities (EIs) in pharmaceutical products may originate from active pharmaceutical ingredients, excipients, manufacturing equipment, utilities, and packaging materials. The ICH Q3D guideline provides a risk-based framework for evaluating and controlling these impurities according to their permitted daily exposure (PDE). This study aimed to perform a comprehensive assessment of elemental impurity risks in an oral solid dosage form using the ICH Q3D component approach (Option 2b), complemented by a quality risk assessment of manufacturing equipment.
Methods: The elemental impurity risk assessment was performed using the component approach (Option 2b), considering the active pharmaceutical ingredient (API), four pharmaceutical excipients, manufacturing equipment, primary packaging, and purified water. Supplier data and available analytical results were used to estimate the daily contribution of Class 1 elements (Cd, Pb, As, and Hg) and Class 2A elements (Co, V, and Ni). The calculated patient exposure was compared with the corresponding oral PDE values established by ICH Q3D. Manufacturing equipment was additionally evaluated using Failure Mode and Effects Analysis (FMEA) to identify potential failure modes and assess the effectiveness of existing control measures.
Results: The API showed consistently low concentrations of the investigated elemental impurities, with values ≤0.1 µg/g across three independent batches. The assessment of the four excipients indicated no intentional addition of the investigated elemental impurities and low overall contributions to patient exposure. Manufacturing equipment presented a negligible residual risk following the implementation of GMP controls, including equipment qualification, cleaning procedures, preventive maintenance, and visual inspection. The estimated total daily exposures were 0.27, 0.27, 0.27, 0.28, 0.29, 0.32, and 1.66 µg/day for Cd, Pb, As, Hg, Co, V, and Ni, respectively. These values corresponded to 5.4%, 5.4%, 1.8%, 0.9%, 0.58%, 0.32%, and 0.83% of their respective PDEs, all remaining well below the 30% PDE threshold used for the control strategy. Primary packaging and purified water were also considered negligible contributors.
Conclusion: The ICH Q3D component approach (Option 2b), combined with systematic quality risk management of manufacturing equipment, provided a practical and scientifically justified framework for elemental impurity assessment in the investigated oral solid dosage form. The estimated exposures were substantially below the applicable PDE values, supporting the adequacy of the existing control measures and indicating that no additional elemental impurity-specific controls were required. This approach may support efficient risk-based decision-making and routine pharmaceutical quality management when reliable supplier and process data are available.
Keywords:
elemental impurities
; risk assessment
; FMEA
; ICH Q3D
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.